NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Rivian Automotive, Inc. (NASDAQ: RIVN)
Class Period: Rivian common stock (1) pursuant to or traceable to Rivian’s Initial Public Offering (“IPO”) on November 10, 2021, and (2) between November 10, 2021, through March 10, 2022, (the "Class Period")
Deadline: May 6, 2022
For more info: www.bgandg.com/rivn.
The Complaint alleges that, in the Registration Statement and throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company's business and operations. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Rivian would not meet its 2021 production and delivery targets; (2) Rivian's vehicles were underpriced and the Company would need to substantially increase prices; and (3) as a result, Defendants' representations about the Company's business, operations, and prospects lacked a reasonable basis.
Akebia Therapeutics, Inc. (NASDAQ: AKBA)
Class Period: June 28, 2018 - September 2, 2020
Deadline: May 13, 2022
For more info: www.bgandg.com/akba.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (2) as a result, Defendants overstated the PRO2TECT Program’s clinical prospects; (3) accordingly, Defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
SafeMoon (SFM)
Class Period: March 8, 2021 - March 7, 2022
Deadline: May 9, 2022
For more info: ww.bgandg.com/sfm.
The complaint alleges that Defendants made false and misleading statements concerning SafeMoon’s growth prospects, financial ownership, and financial benefits for SAFEMOON token investors, and used celebrity promotors to lure in unsuspecting investors so that SafeMoon insiders could sell off their holdings into artificially created volume.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com
